What is VOR's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 1.18B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VOR?

P/E (TTM) is 1.88 and 52-week range is $6.50 to $33.50 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VOR figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for VOR?

The company profile lists net income (TTM) near $-2.33B, EPS (TTM) near $-43.00 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Vor Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Boston, Massachusetts, US, 54.2M shares outstanding, ISIN US9290332074 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Vor Biopharma Inc

$VOR

Health Care · Biotechnology

IR Run Scenarios

$19.90

+4.03%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. The company is headquartered in Boston, Massachusetts and currently employs 76 full-time employees. The company went IPO on 2021-02-05. The firm is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Employees

Website

www.vorbio.com/

IPO

2021-02-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)